Skip to main content
. 2021 Aug 12;21:390. doi: 10.1186/s12872-021-02197-x

Table 2.

Correlation between ELABELA and study variables in all subjects

r P value
Age, years  − 0.300  < 0.001***
Male sex 0.007 0.932
Body mass index, kg/m2 0.158 0.074
Coronary heart disease 0.007 0.926
Diabetes Mellitus  − 0.016 0.840
Hyperlipidemia 0.107 0.174
Systolic blood pressure, mmHg 0.122 0.121
Diastolic blood pressure, mmHg  − 0.010 0.900
Mean arterial pressure, mmHg 0.052 0.513
Heart rate, bpm  − 0.156 0.047*
BNP, pg/ml  − 0.330  < 0.001***
Creatine, umol/l  − 0.134 0.110
Hemoglobin A1C, %  − 0.040 0.648
LDL-c, mmol/l 0.076 0.369
HDL-c, mmo/l 0.084 0.327
Total cholesterol, mmol/l 0.130 0.125
Homocysteine, umol/l  − 0.134 0.113
ESR, mm/h  − 0.073 0.417
Hs-CRP, mg/l  − 0.152 0.100
Troponin I, ng/ml  − 0.010 0.908
LAD, mm  − 0.289 0.001**
LVEDd, mm 0.003 0.976
LVEDs, mm  − 0.089 0.326
LVEF, mm 0.117 0.195
ACEI or ARB 0.096 0.223
Beta blocker 0.052 0.512
CCBs  − 0.046 0.560
Diuretics  − 0.068 0.390

BNP brain natriuretic peptide, LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, ESR erythrocyte sedimentation rate, hs-CRP high-sensitivity C-reactive protein, LAD left atrial diameter, LVEDd left ventricular end diastolic diameter, LVEDs left ventricular end systolic diameter, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor antagonists, CCBs Calcium channel blockers

*P value less than 0.05; **P value less than 0.01; ***P value less than 0.001